DIABETES Add-on to metformin in T2DM-linagliptin or glimepiride?

被引：2
|
作者：
Christensen, Mikkel [2 ]
Knop, Filip K. [1 ]
机构：
[1] Univ Copenhagen, Diabet Res Div, Dept Internal Med, Gentofte Hosp, DK-2900 Hellerup, Denmark
[2] Univ Copenhagen, Bispebjerg Hosp, Dept Clin Pharmacol, DK-2400 Copenhagen, Denmark
来源：
NATURE REVIEWS ENDOCRINOLOGY | 2012年 / 8卷 / 10期
关键词：
HYPOGLYCEMIA; ASSOCIATION;
D O I：
10.1038/nrendo.2012.163
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding between one of the most commonly used second-line agents, glimepiride, and the recently approved dipeptidyl peptidase 4 inhibitor linagliptin.
引用
收藏
页码：576 / 578
页数：3
相关论文
共 50 条
  • [31] COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Gao, L.
    Li, S. C.
    VALUE IN HEALTH, 2012, 15 (07) : A663 - A663
  • [32] Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin
    Hermansen, Kjeld
    Kolotkin, Ronette L.
    Hammer, Mette
    Zdravkovic, Milan
    Matthews, David
    PRIMARY CARE DIABETES, 2010, 4 (02) : 113 - 117
  • [33] Assessment of empagliflozin add-on therapy to metformin and glimepiride in patients with inadequately controlled type-2 diabetes mellitus
    Jawed, Bilal
    Ahmed, Shadab
    Abbas, Syed Qamar
    Ahmed, Zeeshan
    Andleeb, Shomaiza
    Ahmad, Salman Ashfaq
    Asif, Muhammad
    Akhter, Erum
    Ahmed, Salman
    Hussain, Muhammad Waleed
    Iqbal, Adnan
    Ishaqui, Azfar Athar
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 35 (06) : 1733 - 1738
  • [34] Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM)
    Fonseca, Vivian
    Dejager, Sylvie
    Albrecht, Diego
    Shirt, Lynda
    Schweizer, Anja
    DIABETES, 2006, 55 : A111 - A111
  • [35] Empagliflozin as add-on to metformin in patients with Type 2 diabetes
    Merker, L.
    Haering, H. U.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [36] Type 2 diabetes: which drug as add-on to metformin?
    Madsbad, Sten
    LANCET, 2012, 379 (9833): : 2222 - 2223
  • [37] Empagliflozin as add-on to metformin in people with Type 2 diabetes
    Merker, L.
    Haering, H-U.
    Christiansen, A. V.
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 (12) : 1555 - 1567
  • [38] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [39] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin Plus Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Vedel, Anita
    Roux, Christiansen Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A280 - A280
  • [40] COST-EFFECTIVENESS OF TYPE 2 DIABETES (T 2DM) TREATMENT WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN IN THE DOMINICAN REPUBLIC AND GUATEMALA
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Solorzano, J.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2016, 19 (07) : A671 - A672
12345